GS71 Stock Chart & Stats
CHF26.12
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF26.12
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF26.12 - CHF26.12
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
CHF82.08B
Enterprise ValueCHF94.96B
Total Cash (Recent Filing)CHF2.96B
Total Debt (Recent Filing)CHF23.70B
Price to Earnings (P/E)17.2
BetaN/A
Next Earnings
Feb 03, 2027EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.08
Shares Outstanding4,045,430,700
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)4.51
Price to Sales (P/S)2.26
P/FCF Ratio12.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF23.13Price Target Upside-11.45% Downside
Rating ConsensusHold
Number of Analyst Covering15
EPS Forecast (FY)1.98
Revenue Forecast (FY)CHF37.36B
Bulls Say, Bears Say
Bulls Say
Specialty Medicines GrowthBroad-based specialty-medicine growth across HIV, respiratory and oncology reduces reliance on a single product and supports a stronger long-term mix. Double-digit performance from several launches also indicates meaningful commercial traction for GSK’s differentiated portfolio.
Pipeline And Launch MomentumThe sharp acceleration in late-stage development expands GSK’s opportunity to replenish and diversify future revenue. Multiple approvals, launches and positive clinical readouts create several potential growth drivers rather than depending only on established medicines.
Cash Generation And ProfitabilityStrong operating cash flow and free cash flow give GSK internal funding for research, launches, business development and shareholder distributions. High profitability and recent cash-flow growth provide useful resilience while the company invests heavily in its pipeline.
Bears Say
Leverage And Interest BurdenGSK’s meaningful debt load reduces financial flexibility and makes earnings more sensitive to refinancing costs. Higher interest expense, including financing related to Nuvalent, can absorb cash that could otherwise support research, acquisitions or debt reduction.
Rising Investment And Restructuring CostsAccelerated oncology investment may strengthen the pipeline, but the near-term cost burden is substantial and is growing faster than sales. Higher R&D and restructuring charges can limit operating leverage and make earnings conversion less predictable during execution.
Vaccine And Inhaler Market PressurePressure across major commercial franchises creates a drag on portfolio growth even as newer medicines expand. Shingrix faces China ordering and inventory challenges, while inhaler pricing and competition can constrain revenue quality and margin durability.
GS71 FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest stock price was CHF26.11 and its highest was CHF26.11 in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is CHF82.08B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Feb 03, 2027 which is in 94 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Oct 28, 2026. The company reported CHF0.603 earnings per share for the quarter, beating the consensus estimate of CHF0.555 by CHF0.047.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Overvalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline does not currently pay dividends.
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 0.31.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,045,430,700 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of CHF0.603 in its last earnings report, beating expectations of CHF0.555. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in CH:GS71
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GlaxoSmithKline Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF23.13 (-11.45% Downside)
CHF23.13 (-11.45% Downside)
Blogger Sentiment
Neutral
CH:GS71 Sentiment 67%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth CHF2.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 71%
Bearish news 29%
Bearish news 29%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.74%
12-Months-Change
Fundamentals
Return on Equity
24.64%
Trailing 12-Months
Asset Growth
16.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GlaxoSmithKline
GSK plc is a global pharmaceutical and healthcare company, deeply involved in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. Its operations span the United Kingdom, the United States, and numerous other international markets. The company structures its operations across four primary divisions: Pharmaceuticals, Pharmaceutical R&D, Vaccines, and Consumer Healthcare. Within its Pharmaceuticals segment, GSK provides treatments addressing a wide array of therapeutic areas. These include respiratory conditions, HIV, immuno-inflammatory diseases, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital health, metabolic imbalances, bacterial infections, and dermatological issues. The Consumer Healthcare division offers products across categories such as wellness, oral hygiene, nutritional supplements, and skin health. These consumer offerings come in a variety of formats, including oral dosage forms (e.g., tablets, syrups, lozenges, gummies, soft chews, effervescents), topical applications (e.g., gels, creams, patches, lip balms), nasal sprays, and a comprehensive range of oral hygiene products (e.g., toothpastes, mouthwashes, denture care items), alongside other specialized formulations like infant drops and wipes. GSK actively engages in various collaborative ventures. Its collaboration agreements include partnerships with 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Additionally, the company maintains strategic alliances with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. Originally established in 1715, the company operated under the name GlaxoSmithKline plc until its rebranding to GSK plc in May 2022. Its corporate headquarters are situated in Brentford, United Kingdom.
GS71 Stock 12 Month Forecast
Average Price Target
CHF23.13
▼(-11.45% Downside)
Technical Analysis
AstraZeneca
―
Hikma Pharmaceuticals
―
Smith & Nephew
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Haleon PLC
―











